Weight, Prejudice, and Type 2 Diabetes


Do you think overweight people bring Type 2 diabetes on themselves? It would be natural to think that, because doctors and other authorities have been blaming weight for years. Health "experts” call Type 2 a "lifestyle disease," implying that people choose it. Heavy people are called "obese," which comes from the Latin for "over/eating," as if that were the whole cause of overweight. Read More “Weight, Prejudice, and Type 2 Diabetes”

ADVANCE Study Contradicts ACCORD Findings


The surprising and much-publicized early findings from the ACCORD study, which showed a slightly increased risk of death among certain people with Type 2 diabetes who used intensive drug therapy to lower blood glucose levels, have prompted researchers conducting a similar ongoing study to release early results. The ADVANCE study, which is the largest study ever of aggressive blood glucose control in people with Type 2 diabetes, has found no increase in risk of death associated with intensive treatment. Read More “ADVANCE Study Contradicts ACCORD Findings”

Gastric Banding May Help Reverse Type 2


A study published in January in The Journal of the American Medical Association found that gastric banding weight-loss surgery in obese people with Type 2 diabetes led to better blood glucose control and higher rates of diabetes reversal than lifestyle changes meant to help people lose weight. The surgery also helped people lose significantly more weight than lifestyle changes. This was the first randomized study comparing weight-loss surgery to conventional therapy for managing Type 2 diabetes in obese people. Read More “Gastric Banding May Help Reverse Type 2”

The ACCORD Trial Findings: What You Should Know


In one large, ongoing trial of people with Type 2 diabetes and a high risk of cardiovascular disease, intensive blood glucose control has been linked with a slightly higher risk of death compared with less-intensive, "standard" treatment. Participants in the trial who were receiving intensive treatment will now be switched over to standard treatment. While these findings were unexpected and have raised some concerns about diabetes treatment strategies for specific groups of people, they should not trigger a change in therapy for most people with diabetes. Read More “The ACCORD Trial Findings: What You Should Know”

Symlin Now Available in a Pen


The injected diabetes drug pramlintide (brand name Symlin) is now available in pen form. Drug manufacturer Amylin Pharmaceuticals, Inc., announced this week that two new prefilled, pen-injector devices—the SymlinPen 120 and the SymlinPen 60—are now on the market to make the process of injecting mealtime doses of pramlintide simpler and more convenient. Until this week, pramlintide was only available in vials. Read More “Symlin Now Available in a Pen”


The latest delivered straight to your inbox

Learn More


Subscribe to Stay Informed

Sign up for Free

Get the latest diabetes news and a free gift!

Learn More

Save Your Favorites